Feasibility of dose‐dense cisplatin‐based chemotherapy in Japanese children with high‐risk hepatoblastoma: Analysis of the JPLT3‐H pilot study

Watanabe, Kenichiro; Mori, Makiko; Hishiki, Tomoro; Yokoi, Akiko; Ida, Kohmei; Yano, Michihiro; Fujimura, Junya; Nogami, Yuki; Iehara, Tomoko; Hoshino, Ken; Inoue, Takeshi; Tanaka, Yukichi; Miyazaki, Osamu; Takimoto, Tetsuya; Yoshimura, Kenichi; Hiyama, Eiso

doi:10.1002/pbc.29389

Cited by 8 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detailed treatment protocol and outcome of the high-risk feasibility study (JPLT3-H) are published elsewhere [ 12 ]. Details of treatment and outcome in standard-risk and intermediate-risk patients (JPLT3-S, JPLT3-I) are to be published after the designated follow-up is completed.…”

Section: Methodsmentioning

confidence: 99%

Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

In the JPLT3 study, a real-time central surgical reviewing (CSR) system was employed aimed at facilitating early referral of candidates for liver transplantation (LTx) to centers with pediatric LTx services. The expected consequence was surgery, including LTx, conducted at the appropriate time in all cases. This study aimed to review the effect of CSR on institutional surgical decisions in cases enrolled in the JPLT3 study. Real-time CSR was performed in cases in which complex surgeries were expected, using images obtained after two courses of preoperative chemotherapy. Using the cloud-based remote image viewing system, an expert panel consisting of pediatric and transplant surgeons reviewed the images and commented on the expected surgical strategy or the necessity of transferring the patient to a transplant unit. The results were summarized and reported to the treating institutions. A total of 41 reviews were conducted for 35 patients, and 16 cases were evaluated as possible candidates for LTx, with the treating institutions being advised to consult a transplant center. Most of the reviewed cases promptly underwent definitive liver surgeries, including LTx per protocol.

show abstract

Section: Methodsmentioning

confidence: 99%

Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Successful treatment of young childhood standard‐risk hepatoblastoma with cisplatin monotherapy using a central review system

Saeki,

Ida,

Kurihara

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundThe JPLT3‐S (Japanese Study Group for Pediatric Liver Tumors‐3) study, conducted cisplatin (CDDP) monotherapy for young children (<3 years old) with standard‐risk hepatoblastoma (HB) using a central review system in Japan. In the previous JPLT2 study, cases with resectable tumors without any annotation factors in the PRETEXT (PRETreatment EXTent of disease) classification (standard‐risk HB) showed favorable outcomes with treatment consisting of CDDP and pirarubicin, but showed toxicities and late complications. In the JPLT3‐S trial, a less intense regimen consisting of CDDP alone was evaluated.MethodsPatients who were less than 3 years of age and with PRETEXT I, II, or III HB without any annotation factors (e.g., E1, E1a, E2, E2a, H1, N1, P2, P2a, V3, and V3a) were eligible for inclusion in this study. In this trial, the central radiological and pathological features of all patients were reviewed. The primary outcome was the 3‐year progression‐free survival (PFS).ResultsA total of 38 patients (23 female) were included. The median patient age was 12 months (range: 2–34). Two patients discontinued treatment because of progressive disease, and five patients discontinued treatment for other reasons. The 3‐year PFS rate was 93.9% (95% confidence interval [CI]: 86.4%–100%). All 38 patients survived (follow‐up period 38–98 months), and the OS rate was 100% (CI: 100). Eighteen of the 38 patients (47.4%) experienced ototoxicity as a late complication.ConclusionCDDP monotherapy regimen is feasible in young patients with localized HB, as classified by a central review.

show abstract

Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases

Wang

Zhang

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Feasibility of dose‐dense cisplatin‐based chemotherapy in Japanese children with high‐risk hepatoblastoma: Analysis of the JPLT3‐H pilot study

Cited by 8 publications

References 26 publications

Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial

Feasibility of Real-Time Central Surgical Review for Patients with Advanced-Stage Hepatoblastoma in the JPLT3 Trial

Successful treatment of young childhood standard‐risk hepatoblastoma with cisplatin monotherapy using a central review system

Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases

Contact Info

Product

Resources

About